NCT00480636View on ClinicalTrials.gov

Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients

CompletedOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Acute Deep Vein Thrombosis
Interventions
DRUG

Fragmin (dalteparin sodium )

Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY